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Abstract
Metabolic syndrome refers to the coexistence of insulin resistance (IR) with 
several risk factors, including abdominal obesity, atherogenic dyslipidemia, and 
hypertension, which is usually complicated by cardiovascular and/or cerebrovas-
cular diseases. This clustering of risk factors suggests that they are interrelated 
and not independent of one another and that they share underlying mechanisms, 
mediators, and pathways. Its prevalence exceeds 40% of those over 40, and it has 
recently been diagnosed in adolescents and even children. Metabolic syndrome is 
a pro-inflammatory prothrombotic state with determination of elevated level of 
cytokines, acute phase reactants, fibrinogen, and plasminogen activator inhibi-
tor-1. A comprehensive definition of metabolic syndrome and its pathogenesis 
would facilitate research into its causes and disease pathophysiology linking the 
components of metabolic syndrome with the increased risk of cardiovascular 
diseases. The management to mitigate these underlying risk factors constitutes a 
first-line intervention; dietary therapy of metabolic syndrome includes lifestyle 
modification, hypocaloric diet, and consumption of functional food. Healthy 
food quantity and time of consumption help restore the normal metabolic 
profiles. Hopefully, this will lead to new insights into facilitating epidemiologi-
cal and clinical studies of pharmacological, lifestyle, and preventive treatment 
approaches.
Keywords: metabolic syndrome, circadian rhythm, insulin resistance, sleep, 
functional foods, lifestyle modification, hypocaloric diets
1. Introduction
The prevalence of metabolic syndrome (MetS) worldwide varies between 10 and 
84% depending on the age, gender, and race of the population [1]. The International 
Diabetes Federation estimates that one-quarter of the world’s population has MetS 
[2]. Although the prevalence of MetS varies throughout the world and depends on 
the particular health organization used for its definition, it is clear that the number 
of people complaining about this syndrome has globally risen [3], due to a more 
sedentary life, the increase in the number of smokers, unhealthy dietary habits, and 
the increase in stress [4].
MetS is a cluster of metabolic disturbances that tend to coexist. Different health 
organizations have suggested diverse definitions for MetS. However, it is clear that 
MetS is a clinical entity of substantial heterogeneity, commonly represented by the 
combination of central abdominal obesity, hyperglycemia, dyslipidemia, and/or 
hypertension [5, 6].
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In 1994, the World Health Organization [7] defined MetS as the presence of 
one of the following: type II diabetes mellitus, insulin resistance, or impaired 
glucose tolerance, plus at least two of the following—triglycerides (TG) ≥150 mg/
dL (≥1.7 mmol/L) and/or HDL cholesterol <40 mg/dL (≤0.9 mmol/L) (males) and 
<50 mg/dL (≤1.0 mmol/L) (females); urine albumin excretion >20 g/min or albu-
min/creatinine ratio >30 mg/g; systolic blood pressure ≥140 mmHg or diastolic blood 
pressure ≥90 mmHg or a prescription of hypertension; and central obesity, waist 
circumference (WC) ≥102 cm (males) and ≥ 88 cm (females), waist/hip ratio > 0.90 
(males) and >0.85 (females), and/or body mass index (BMI) >30 kg/m2 [8].
The International Diabetes Federation defined MetS as encompassing at least 
three of the following five conditions: (1) male waist circumference ≥ 94 cm and 
female waist circumference ≥ 80 cm; (2) fasting glucose level ≥ 100 mg/dL; (3) SBP 
≥130 and/or DBP ≥85 mmHg or under medical treatment for hypertension; (4) TG 
≥150 mg/dL or ≥ 1.7 mmol/L or prescribed pharmacological treatment for hypertri-
glyceridemia; or (5) male HDL cholesterol <40 mg/dL and female HDL cholesterol 
<50 mg/dL [9].
Other markers used for diagnosis of metabolic syndrome include high-sensi-
tivity C-reactive protein concentrations (hs-CRP) ≥3 mg/dL [10], uric acid [11], 
fibrinogen [12], plasminogen activator inhibitor-1 [13, 14], increased homocys-
teine [15, 16], and decreased adiponectin [17]. Fibrinogen, plasminogen activator 
inhibitor-1, cytokines, and hs-CRP protein are often elevated in patients with MetS, 
resulting in a prothrombotic and pro-inflammatory state. These biomarkers are 
not routinely evaluated in clinical practice. hs-CRP ≥3 mg/dL indicates a state of 
inflammation and a higher risk of atherosclerotic cardiovascular disease (ASCVD).
2. Characterization and risk assessment
MetS is a link between visceral adiposity, insulin resistance, inflammation, and 
endothelial dysfunctions [18, 19].
2.1 Visceral adiposity
Visceral adiposity (abdominal fats close to the visceral organs) leads to an 
imbalance in the secretion of pro-inflammatory and anti-inflammatory factors. 
Adipocytes produce pro-inflammatory factors in excess, such as IL-6, IL-10, TNF-ɑ, 
and hs-CRP. These cytokines block the intracellular insulin signaling pathways. 
Moreover, the adipose tissue inhibits adiponectin [20, 21].
2.2 Insulin resistance
Insulin resistance (IR) rises with increased waist circumference or body fat and 
is not related to the body mass index. IR results in the diversion of excess non-
estrified fatty acids from lipid-overloaded IR muscles to the hepatic cells, resulting 
in nonalcoholic fatty liver disease and atherogenic dyslipidemia. IR predisposes to 
glucose intolerance, which may be aggravated by increased hepatic gluconeogenesis 
with an IR liver [22].
2.3 Pro-inflammatory condition
Inflammation is a response of the immune system to injury. It is a mechanism in 
the pathogenesis and progression of obesity-related medical disorders and the link 
between adiposity, IR, MetS, and cardiovascular disease [23]. Oxidative stress is a 
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condition in which there is an imbalance between the prooxidants and antioxidants 
in the body [24]. It plays a key role in the pathogenesis of atherosclerosis through 
different mechanisms such as the oxidation of LDL-c particles [24, 25] or the 
impairment of HDL-c functions [26].
2.4 High blood pressure
Hypertension is defined as a resting SBP ≥140 mmHg and/or DBP ≥90 mmHg 
or the use of medical prescription to lower blood pressure [27]. Activation of the 
sympathetic nervous system together with the activation of the renin-angiotensin 
system by the hyperglycemia and antinatriuretic effect of insulin, in addition to 
some obese people being salt sensitive, contributes to the development of hyper-
tension. It is identified as a major cardiovascular and renal risk factor related 
to heart disease, myocardial infarction, cerebrovascular stroke, and vascular 
diseases [28].
2.5 Circadian rhythm disruption
Over the last two decades, a deeper comprehension of the molecular mecha-
nisms that control the biological clock and circadian rhythm has been achieved. 
The 2017 Nobel Prize in Physiology was awarded to Jeffrey C. Hall, Michael 
Rosbash, and Michael Young for their work on circadian rhythms [29, 30]. There 
are interconnections between the circadian rhythm and endocrine homeostasis. 
Biological clock disruption was in fact associated to an increased incidence of 
metabolic and endocrine diseases. Irregular rhythms have been linked to vari-
ous chronic health conditions, such as sleep disorders, obesity, type II diabetes 
mellitus, hypertension, gastrointestinal motility diseases, depression, cardiac 
diseases, cognitive dysfunction, bipolar disorder, and seasonal affective disorder 
[31]. The master clock in mammals that controls circadian rhythms consists of a 
group of nerve cells in the brain called the suprachiasmatic nucleus (SCN) which 
contains about 20,000 nerve cells. It is located in the hypothalamus superior to 
the optic chiasm and receives direct light information from the retina via the 
retinohypothalamic tract. The master clock in the brain coordinates all of the 
body’s peripheral clocks through different neural and humoral signals, so they are 
in synchrony [32].
The nonstop 24/7 lifestyle has given rise to human clock gene mutation, for 
which the human biological clock does not have a suitable design for physiologi-
cal adaptation; this leads to an imbalance of autonomic nervous system function 
toward the parasympathetic predominance in the abdominal compartment and the 
sympathetic predominance in the muscular and thoracic compartments, resulting 
in the impairment of insulin secretion, glucose uptake by the muscle, and increase 
in blood pressure, intra-abdominal fat, and fatty liver [33].
The timing and nutritional composition of meals can regulate circadian 
rhythms, particularly in the peripheral tissue. The translation of these findings to 
human physiology now represents an important goal. In healthy humans, glucose 
tolerance lowers throughout the day, leading to the term “afternoon diabetes”; a 
daily rhythm in pancreatic insulin production is observed, with increased insulin 
production in the morning compared to the evening. Moreover, lipid metabolism 
exhibits circadian regulation, with elevated plasma concentrations of triacylglyc-
erol during the biological night and an elevated postprandial response following 
a nighttime meal compared with the same meal consumed during the day [34]. In 
2006, Staels stated “When the clock stops ticking, metabolic syndrome explodes” 
[35]. When to eat is as important as what to eat.
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2.5.1 Sleep in relation to melatonin and growth hormone secretions
Melatonin is synthesized by multiple tissues in the body, but the pineal gland is 
the major contributor to circulating melatonin concentration. The rhythmic activity 
of the SCN determines the release of melatonin, which directly correlates with day 
length, and it may in turn modulate other physiological functions through paracrine 
signaling. Pancreatic hormone insulin, gastric hormone ghrelin, growth hormone 
(GH) from the pituitary gland, and leptin hormone represent as key factors in 
metabolic regulation, and now several circadian factors are recognized as regulators 
of their secretion and activity. Sleep deprivation results in circadian misalignment 
and increases markers of inflammation and IR. A better understanding of such 
relationships might prove useful and supportive in designing new therapeutic 
approaches for metabolic syndrome [36].
Growth hormone is a peptide hormone secreted by the anterior pituitary under 
control of the hypothalamic-pituitary axis. Actions of GH depend on the age of 
the individual. The primary role of GH in children and adolescents is to promote 
growth until the final adult height is achieved, while in adults, the role of GH is the 
regulation of protein, carbohydrate, and lipid metabolism, insulin resistance, and 
metabolic homeostasis. Sleep restriction and disturbance have also been shown 
to negatively impact hormone secretion. In sleep deprivation cases, GH secretion 
decreases, the appetite-suppressing hormone leptin decreases, and the appetite-
stimulating hormone ghrelin increases. The end result is the consumption of 
additional food and calories. Plasma GH peak appeared with the onset of deep sleep 
and did not correlate with the changes in plasma glucose and insulin. GH secretion 
decreased if the onset of sleep was delayed [37].
2.6 Risk assessment
Metabolic syndrome directly promotes the development of atherosclerotic car-
diovascular disease (ASCVD) [38] and type II diabetes mellitus [39]. Atherogenic 
dyslipidemia, high circulating levels of prothrombotic factors, and the increase of 
inflammatory markers carry a higher risk for acute cardiovascular syndromes [40]. 
Previous studies on middle-aged persons with metabolic syndrome had concluded 
that many middle-aged people are at increased absolute risk for cardiovascular dis-
eases in the 10-year risk. Furthermore, in young adults who develop the syndrome, 
long-term risk for ASCVD is increased even when the 10-year risk is not high. The 
Framingham risk scoring is used to classify metabolic syndrome patients into three 
risk categories based on a 10-year risk for coronary heart disease, cerebrovascular 
disease, peripheral artery disease, and heart failure risk: low-risk (10-year risk 
<10%), moderate-risk (10-year risk 10–20%), and high-risk patients (10-year risk 
>20%) [41, 42].
3. Metabolic syndrome, mental and cognitive functions
Obesity and dementia frequently coexist. They share many common pathways 
such as insulin resistance as well as inflammation and oxidative stress. Midlife 
obesity is directly related to the risk of developing dementia later in life. Dementia 
is a syndrome characterized by gradual decline in cognitive functions (memory, 
attention, behavior, language, mood, and learning). In 2008, Dr. Suzanne de la 
Monte and Dr. Jack Wands proposed that Alzheimer’s disease could be termed type 
III diabetes, based on the fact that IR within the brain revealed to be a characteristic 
of Alzheimer’s disease [43]. There is no definite cure for dementia, and prevention 
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is the only option. Prevention may be achieved by early treatment of the risk factors 
resulting in cognitive impairments (obesity, DM, HTN, smoking, dyslipidemia, 
anxiety, and depression). Several biomarkers could be involved in the pathogenesis 
of mild cognitive impairment or early neurodegenerative diseases. Assessment 
of these biomarkers in obese middle-aged persons could serve as a basis for early 
management to alleviate the burden of cognitive impairment and dementia in the 
future.
3.1 Cognitive and mental evaluations
The Mini-Mental State Examination (MMSE) was performed for clinical evalua-
tion of mental and cognitive status. The 30-point questionnaires take between 5 and 
10 minutes and examination functions including registration, attention, calcula-
tion, recall, language, commands, and orientation [44]. It is a sensitive, valid, and 
reliable method that is used extensively in clinical and research settings to measure 
cognitive impairment and to estimate the severity and progression of cognitive 
impairment. It is also used to follow the course of cognitive changes in an individual 
over time, thus making it an effective way to document an individual’s response 
to treatment. Sleep quality and the number of sleep hours and their pattern were 
evaluated. Exposure to sun and length of time, duration, and clothing were 
recorded. General subjective life stresses, life pattern to evaluate general activity, 
and history of exercising were recorded.
C-peptide was detected by C-peptide enzyme immunoassay [45]. Modified 
homeostatic model assessment of insulin resistance (M.HOMA-IR) was calcu-
lated by Eq. (1), in which insulin was replaced by C-peptide so as to be applied on 
diabetic patients using exogenous insulin [46]:
  M .HOMA − IR = 1.5 + Fasting blood glucose × Fasting c − peptide / 2800     (1)
Blood sampling and biochemical markers of cognitive function impairments 
were performed as ceramide kinase enzyme, alpha-synuclein, serum clusterin, 
amyloid beta, and inflammatory markers (hs-CRP, IL-6, and TNF-α).
Ceramides are agents involved in the pathogenesis of mild cognitive impairment 
or early neurodegenerative diseases. They are mediated by insulin resistance and 
inflammatory states. Ceramides are lipid soluble and therefore likely to readily 
cross the blood-brain barrier resulting in cytotoxic effects in the central nervous 
system with various dementia-associated diseases, including Alzheimer’s disease. 
It is important to prevent its elevation in the human body via increasing the activ-
ity of the ceramide kinase enzyme (CERK enzyme) that converts the ceramide to 
ceramide-1-phosphate (C1P) via its phosphorylation. C1P is a sphingolipid metabo-
lite that has been implicated in the membrane fusion of brain synaptic vesicles and 
neutrophil phagolysosome formation. C1P is a key regulator of cell growth and 
survival, it stimulates DNA synthesis and cell division, and it is a potent inhibitor 
of apoptosis. Many studies have shown that C1P is important for membrane biol-
ogy and for the regulation of membrane-bound proteins and the CERK enzyme 
has appeared to be tightly regulated in order to control both ceramide levels and 
production of C1P [47]. Improvement of the metabolic profiles including C-peptide 
concentration and the M.HOMA-IR values was associated with the improvement of 
the serum level of the enzyme CERK and of cognitive functions [48].
Alpha-synuclein (α-Syn) protein was originally isolated from Alzheimer’s 
disease plaques and was thought to be a presynaptic nerve terminal protein. The 
α-Syn is a member of the synuclein’s family of cytoplasmic, predominantly neuron-
specific proteins. Synucleins are small, prone to aggregate proteins associated 
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with several neurodegenerative diseases. The α-Syn has been found in body fluids, 
including blood and cerebrospinal fluid, peripheral tissues, and the central ner-
vous system. Previous reports suggest that α-Syn is widely expressed peripherally, 
including the macrophages. The expression of α-Syn is enhanced in activated mac-
rophages, suggesting that α-Syn may modulate macrophage function and thereby 
inflammatory processes. Diet-induced obesity may be an environmental risk factor 
for the development alpha-synucleinopathies [49]. There was a significant positive 
correlation between serum IL-6 and serum α-Syn. Fighting obesity, dyslipidemia, 
and the associated complications especially the inflammatory processes improved 
the deleterious effects on the cognitive functions in obese persons [50].
Clusterin (apolipoprotein J) is a heterodimeric glycoprotein in which α and 
β chains are interconnected via five disulfide bonds. There is a strong associa-
tion between the single-nucleotide polymorphisms in the clusterin gene and 
Alzheimer’s disease. Moreover, plasma clusterin is considered a potential periph-
eral biomarker of cognitive dysfunction and AD. Clusterin may be related to AD 
pathogenesis through various mechanisms. It could bind amyloid extracellularly 
and inhibit the aggregation of amyloid beta monomers into toxic oligomers. In 
addition, the neurotoxicity of the amyloid might be reduced by the interaction 
of clusterin with the molecules involved in signal transduction, DNA repair, cell 
cycle, and apoptosis. Brain apolipoprotein clusterin plays an important role in 
cholesterol transport and neuronal lipid metabolism. Furthermore, it has a role in 
the inhibition of neuroinflammation which is thought to be a major factor in AD 
pathogenesis and identified as a key component in cerebrovascular diseases. In 
addition, it is known that neuroinflammation plays an important role in dementia 
pathogenesis and neurodegenerative diseases [51, 52]. The improvement of the 
C-peptide concentration and the M.HOMA values were parallel with improvement 
of oral cognitive tests and clusterin value; clusterin was presented as a cognitive 
function parameter [52].
Plasma amyloid beta (Aβ) can be applied as trait, risk, or state biomarker for AD 
and denote a neuropathologic condition. A previous study has reported the pres-
ence of a stronger correlation between plasma Aβ and positron emission tomogra-
phy or Pittsburgh Compound-B-C11 as radiotracers illustrate fibrillar brain amyloid 
deposits which is a reliable method to measure brain amyloid plaque accumulation. 
Reduction of body weight and improving the metabolic profile reduced the level 
of serum Aβ protein, an effective role in improving the cognitive function. At the 
same time, previous studies stated that plasma Aβ measures possibly aid in clini-
cal investigations as markers for the pharmacological impacts of medications that 
influence amyloid protein transformation [53].
Serum hs-CRP level may be used as a marker for cognitive functions in obese 
middle-aged persons. Peripheral inflammatory markers are elevated in obese 
patients. Improvement in cognitive functions is recorded after dietary therapy, with 
decrease in hs-CRP serum levels. Significant inverse correlation is found between 
cognitive functions and hs-CRP levels, insulin resistance, minimal waist circumfer-
ence, and BMI [54].
4. Management of metabolic syndrome
As the presence of MetS carries a risk for cardiovascular diseases and diabetes 
mellitus, the primary goal of clinical management to individuals with metabolic 
syndrome is directed towards decreasing the major metabolic risk factors: high 
LDL-C, hypertension, obesity by losing fat percentage and not muscle mass, 
decreasing insulin resistance, blood glucose, and maintaining normal HDL and 
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triglyceride levels through lifestyle changes. Moreover, medical drug therapy might 
be considered in high-risk patients to modify cardiovascular disease risk factors [7]. 
Bariatric surgery has been indicated to treat morbidly obese persons. The safety and 
effectiveness of bariatric surgery in patients with metabolic syndrome have been 
studied and encouraged [55, 56].
Chronotherapy means the timing of drug and dietary treatment to obtain 
maximum therapeutic effect. It can be achieved through the timing of light expo-
sure, exercise, food consumption, medication uptake, and sleep, with the goal 
of optimizing any treatment by taking into account the circadian rhythms of the 
body [57].
4.1 Therapeutic lifestyle modifications
Physical exercise, diet, and adequate sleep are the way to reach the target. 
Gradual permanent change in the patient’s lifestyle can lead to better and easily 
maintain normal parameters than major food deprivation introduced all at once. 
Implementing the following changes increases the chances of success: changing a 
sedentary life through regular sustained physical exercise and eating several small 
portions of different foods varieties; consuming complex carbohydrates such as 
barley, oat, corn, quinoa, and brown rice while decreasing the consumption of 
simple carbohydrates such as white sugar and sweets; eating fresh seasonal fruit 
and vegetables daily as they are good sources of fiber, vitamins, and minerals noting 
that dietary fiber helps prevent gastrointestinal problems such as flatulence and 
constipation; eating foods rich in unsaturated fatty acids such as salmon, mackerel, 
sardines, tuna, raw nuts, and flaxseed oil; increasing the consumption of black 
beans, kidney beans, green peas, and lentils; avoiding processed and red meats; 
limiting the intake of sugar, salt, and carbonated drinks; replacing salt with spices; 
boiling, baking, or steaming food instead of frying; paying attention to portion size 
by utilizing smaller plates; and drinking plenty of fluids, of which 30 ml/kg/day 
water is the best [7].
Avoid light exposure in late evening or at night as artificial light disrupts the cir-
cadian rhythm and the production of melatonin and therefore has a negative effect 
on sleep quality, mood, cognition, and hormonal functions [58, 59]. Sleep early and 
get at least 6 hours of sleep per night [60], and stop smoking.
4.2 Energy-restricted diets
For our patients, the Harris-Benedict equation (Eq. (2)) was used to calculate 
the caloric requirements for each individual in order to estimate the caloric needs or 
basal energy expenditure (BEE) as follows [61]:
  Males : BEE = 66.5 + 13.8  (weight in Kg) + 5  (height in cm) –6.8  (age) . 
Females : BEE = 65.5 + 9.6  (weight in Kg) + 1.7  (height in cm) –4.7  (age) .     
(2)
These equations yield basal energy expenditure that is frequently multiplied 
by various activities and/or stress factors to generate the patient’s estimated 
resting energy expenditure, and then we subtracted 500 calories per week from 
the calculated energy requirement, to produce weight loss of 0.5–1 kg per week. A 
hypocaloric diet goal is to reduce body weight by about 10% over the first 6 months. 
The menu varied according to the participant’s age and eating habits. It was low in 
fat (20–25%), high in complex carbohydrate (50–60%), and sufficient in protein 
(25–30%) from both animal and vegetarian sources [54]. Carbohydrates in the 
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form of complex CHO, which have low glycemic loads and indexes such as whole 
grains, oats, fresh seasonal fruits, and vegetables, were consumed to increase high 
fiber content (eight servings of fresh vegetables and fruits/day). On the other hand, 
they were instructed to decrease foods rich in saturated fats such as fried foods and 
packaged meats [62].
4.3 The Mediterranean diet
The Mediterranean diet (MedDiet) is based on scientific evidence that 
inhabitants of Mediterranean countries (Greece, Italy, and Spain), around the 
Mediterranean Sea adhering to the principles of nutrition traditional for their 
region, have better health indicators than people in other areas. Originally, it was 
developed to prevent and treat the symptoms of hypertension and/or heart disease. 
In this MedDiet, the emphasis is on the use of plant-based foods as the main source 
of nourishment: fruits, vegetables, cereals, nuts, legumes, seeds, and whole grains. 
It is also recommended to replace butter and hydrogenated fats with extra-virgin 
olive oil and salts with spices and herbs. Red meat and sweets should be eaten once 
a week, and the main sources of protein should be eggs, yoghurt, fish, and poultry. 
Red wine could be taken in limited amounts (one glass per day for women; two 
glasses per day for men) [63–65].
4.4 Role of functional foods
There is no universal definition for functional foods, but the easiest one is from 
the International Food Information Council which described functional foods as 
“dietary or food components that provide a health benefit beyond providing basic 
nutrition” [55]. Functional foods have an important role in the management of 
metabolic syndrome. Functional foods can help in weight loss, regulation of blood 
pressure, and control of blood glucose and lipid profile levels. Previous studies 
supported the beneficial effects of using functional foods containing bioactive 
components in the management of metabolic syndrome. This includes the intake 
of foods which have a thermogenesis effect (process in which body heat produc-
tion increases, e.g., ginger, caffeine, red pepper, and green tea); functional foods 
with anti-inflammatory properties such as curcumin; and foods with the ability to 
increase insulin sensitivity, e.g., cinnamon, and increase intake of foods rich in plant 
estrogens such as soymilk, soybeans, flaxseed, sesame, green beans, fennel, pea-
nut, and pumpkin seeds. In addition, soy products are rich in amino acids and can 
preserve lean body mass, decrease body fat percentage, and increase basal metabolic 
rate [48, 50, 53, 66–70].
4.4.1 Functional food classification
• Natural functional foods: food products rich in biological active compounds (food 
rich in dietary fiber such as oat, barley, psyllium, vegetables, and fruits) [66]
• Foods with approved scientific heath nutrients: apple (pectin), garlic (Allium 
sativum), and fish (omega 3 fatty acids) [71]
• Fortified foods with specific nutrients: iron fortified chocolate for iron defi-
ciency anemia, calcium fortified juices, and zinc fortified products
• Fermented products rich in probiotics or synbiotics [72]
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4.4.2 Eat to beat metabolic syndrome
The use of functional and prepared designed food would help fight MetS. Three 
thousand years ago, Hippocrates announced the tenet “Let food be thy medicine 
and medicine be thy food.” Dietary supplements proved to improve the MetS 
criteria which include Syrian bread prepared mainly from barley flour and wheat 
germ mixed with either turmeric or ginger; doum biscuits; barley biscuits; bread 
pre pared with soybean flour and enriched with curcumin or ginger; and cookies 
prepared with whole wheat flour and fennel or chia seeds. The higher fiber content 
of these products has a satiety effect so as to decrease food consumption. Moreover, 
fibers decrease digestion and absorption of dietary carbohydrates. Soy flour is a very 
rich source of essential amino acids except methionine. Preparation of bakery prod-
ucts using bioactive ingredients has positive beneficial effects for obesity, diabetes, 
and dyslipidemia management. These compounds have different benefits such as 
anti-atherogenic, antioxidant, and anti-inflammatory effects [48, 50, 53, 67–70].
4.5 Pharmacological management
There are no specific recommendations regarding the pharmacological manage-
ment of metabolic syndrome; instead, the focus is on the management of the risk 
factors which need to be aggressively treated in order to prevent cardiovascular 
disease and type II diabetes mellitus if lifestyle changes aren’t enough to reduce the 
risks. The available evidence of the pharmacological prescriptions is related to their 
cardiovascular benefits in clinical practice. Pharmacological treatments include 
statins and/or fibrates for dyslipidemia, angiotensin-converting enzyme inhibitors 
or renin-angiotensin-aldosterone system inhibitors for hypertension, metformin 
or sodium/glucose cotransporter 2 inhibitors or glucagon-like peptide 1 receptor 
agonists (GLP-1RAs) for glucose intolerance, and low-dose aspirin for prevention of 
arterial thrombosis [73]. Melatonin provides an innovative approach in the manage-
ment of MetS through its useful effects on circadian rhythmicity, insulin resistance, 
dyslipidemia, high blood pressure, weight loss, and improving the antioxidative 
status (melatonin tablet 1 mg/kg) [74, 75]. Melatonin reduces the toxicity of many 
pharmaceutical agents and has a high safety profile [76].
5. Conclusion
Prevention is the best form of treatment of metabolic syndrome, and it starts 
from childhood by following a healthy lifestyle based on proper nutrition, exercise, 
and adequate early night sleep. Timing of food consumption, food quality, food 
quantity, light exposure, medication intake, and sleep are likely to play an impor-
tant role in human health. Eat small portion sizes of food, and follow the rhythm of 
the day to maintain the synchronicity of the biological clock. Consuming natural 
effective supplements rich in bioactive substances leads toward the optimization of 
biochemical parameters of patients with metabolic syndrome in favor of a healthy 
outcome. Bariatric surgery should be considered in individuals with morbid obesity 
or obesity associated with comorbidity.
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Abbreviations
ASCVD atherosclerotic cardiovascular disease
α-Syn alpha-synuclein
AD Alzheimer’s disease
Aβ amyloid beta
BEE basal energy expenditure
BMI body mass index
C1P cermide-1-phosphate
CERK ceramide kinase enzyme
CRP C-reactive protein
DBP diastolic blood pressure
DM diabetes mellitus
GLP-1RAs glucagon-like peptide 1 receptor agonists
GH growth hormone
HDL-c high-density lipoprotein cholesterol
hs-CRP high-sensitivity C-reactive protein
IL-6 interleukin-6
IL-10 interleukin-10
IR insulin resistance
LDL-c low-density lipoprotein cholesterol
MedDiet Mediterranean diet
MetS metabolic syndrome
M.HOMA-IR modified homeostatic model assessment of insulin resistance
MMSE mini-mental state examination
SBP systolic blood pressure
SCN suprachiasmatic nucleus
TG triglycerides
TNF-ɑ tumor necrosis factor-ɑ
WC waist circumference
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